Anti-Nogo-A monoclonal antibody IN1

Drug Profile

Anti-Nogo-A monoclonal antibody IN1

Alternative Names: mAb IN1; monoclonal antibody IN1

Latest Information Update: 19 Jul 2010

Price : $50

At a glance

  • Originator University of Zurich
  • Developer Novartis; University of Zurich
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Phase I Spinal cord injuries
  • Preclinical CNS trauma

Most Recent Events

  • 02 Nov 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Neurological disorders pharmacodynamics section
  • 07 Jul 2006 Phase-I clinical trials in Spinal cord injuries in Switzerland (Implant,Injection)
  • 13 Dec 2005 Preclinical trials in CNS trauma in Switzerland (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top